265 related articles for article (PubMed ID: 21770740)
21. Choroidal neovascularization in pathologic myopia: intravitreal ranibizumab versus bevacizumab--a randomized controlled trial.
Gharbiya M; Giustolisi R; Allievi F; Fantozzi N; Mazzeo L; Scavella V; Gabrieli CB
Am J Ophthalmol; 2010 Mar; 149(3):458-64.e1. PubMed ID: 20172072
[TBL] [Abstract][Full Text] [Related]
22. Intravitreal ranibizumab versus bevacizumab for treatment of myopic choroidal neovascularization.
Iacono P; Parodi MB; Papayannis A; Kontadakis S; Sheth S; Cascavilla ML; Bandello F
Retina; 2012 Sep; 32(8):1539-46. PubMed ID: 22922846
[TBL] [Abstract][Full Text] [Related]
23. [Intravitreal injection of bevacizumab for naive myopic choroidal neovascularization: 19-month results].
De Bats F; Grange JD; Denis P; Kodjikian L
J Fr Ophtalmol; 2013 Jan; 36(1):12-8. PubMed ID: 23219506
[TBL] [Abstract][Full Text] [Related]
24. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularisation: 1-year results of a prospective pilot study.
Chan WM; Lai TY; Liu DT; Lam DS
Br J Ophthalmol; 2009 Feb; 93(2):150-4. PubMed ID: 18801766
[TBL] [Abstract][Full Text] [Related]
25. Two-year outcome of intravitreal injections of ranibizumab for myopic choroidal neovascularization.
Wu TT; Kung YH
J Ocul Pharmacol Ther; 2014 Dec; 30(10):837-41. PubMed ID: 25162313
[TBL] [Abstract][Full Text] [Related]
26. FACTORS INFLUENCING NEED FOR RETREATMENT AND LONG-TERM VISUAL OUTCOME AFTER INTRAVITREAL BEVACIZUMAB FOR MYOPIC CHOROIDAL NEOVASCULARIZATION.
Ng DS; Kwok AK; Tong JM; Chan CW; Li WW
Retina; 2015 Dec; 35(12):2457-68. PubMed ID: 26035400
[TBL] [Abstract][Full Text] [Related]
27. Intravitreal bevacizumab for treatment of myopic choroidal neovascularization: the second year of a prospective study.
Gharbiya M; Allievi F; Conflitti S; Esposito M; Scavella V; Moramarco A; Cruciani F
Clin Ter; 2010; 161(3):e87-93. PubMed ID: 20589348
[TBL] [Abstract][Full Text] [Related]
28. Intravitreal bevacizumab for inflammatory choroidal neovascularization: results from the Pan-American Collaborative Retina Study Group at 24 months.
Arevalo JF; Adan A; Berrocal MH; Espinoza JV; Maia M; Wu L; Roca JA; Quiroz-Mercado H; Ruiz-Moreno JM; Serrano MA;
Retina; 2011 Feb; 31(2):353-63. PubMed ID: 20890239
[TBL] [Abstract][Full Text] [Related]
29. Long-term results of intravitreal bevacizumab injection for choroidal neovascularization secondary to angioid streaks.
Sawa M; Gomi F; Tsujikawa M; Sakaguchi H; Tano Y
Am J Ophthalmol; 2009 Oct; 148(4):584-590.e2. PubMed ID: 19541288
[TBL] [Abstract][Full Text] [Related]
30. Intravitreal bevacizumab for myopic choroidal neovascularization: short-term and 1-year results.
Spielberg L; Leys A
Bull Soc Belge Ophtalmol; 2009; (312):17-27. PubMed ID: 19927486
[TBL] [Abstract][Full Text] [Related]
31. Short-term effects of intravitreal bevacizumab for subfoveal choroidal neovascularization in pathologic myopia.
Hernández-Rojas ML; Quiroz-Mercado H; Dalma-Weiszhausz J; Fromow-Guerra J; Amaya-Espinosa A; Solís-Vivanco A; Reyna-Castelán E; Abraham-Marín M; Martínez-Castellanos MA; Aiello LP
Retina; 2007; 27(6):707-12. PubMed ID: 17621179
[TBL] [Abstract][Full Text] [Related]
32. Intravitreal anti-VEGF therapy for choroidal neovascularisation secondary to pathological myopia: 4-year outcome.
Ruiz-Moreno JM; Arias L; Montero JA; Carneiro A; Silva R
Br J Ophthalmol; 2013 Nov; 97(11):1447-50. PubMed ID: 24026146
[TBL] [Abstract][Full Text] [Related]
33. Ranibizumab treatment for choroidal neovascularization secondary to causes other than age-related macular degeneration with good baseline visual acuity.
Erol MK; Ozdemir O; Coban DT; Ceran BB; Bulut M
Semin Ophthalmol; 2014 Mar; 29(2):108-13. PubMed ID: 24409939
[TBL] [Abstract][Full Text] [Related]
34. Long-term follow-up of myopic choroidal neovascularization treated with ranibizumab.
Franqueira N; Cachulo ML; Pires I; Fonseca P; Marques I; Figueira J; Silva R
Ophthalmologica; 2012; 227(1):39-44. PubMed ID: 22056757
[TBL] [Abstract][Full Text] [Related]
35. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].
Bidot ML; Malvitte L; Bidot S; Bron A; Creuzot-Garcher C
J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687
[TBL] [Abstract][Full Text] [Related]
36. Intravitreal bevacizumab for treatment-naïve subfoveal occult choroidal neovascularization in age-related macular degeneration.
Furino C; Boscia F; Recchimurzo N; Besozzi G; Cardascia N; Sborgia L; Niro A; Sborgia C
Acta Ophthalmol; 2009 Jun; 87(4):404-7. PubMed ID: 18782335
[TBL] [Abstract][Full Text] [Related]
37. One-year outcomes of less frequent bevacizumab in age-related macular degeneration.
Sonmez K; Sonmez PA; Ozkan SS; Atmaca LS
Retina; 2011 Apr; 31(4):645-53. PubMed ID: 21358363
[TBL] [Abstract][Full Text] [Related]
38. Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia.
Yamamoto I; Rogers AH; Reichel E; Yates PA; Duker JS
Br J Ophthalmol; 2007 Feb; 91(2):157-60. PubMed ID: 16870653
[TBL] [Abstract][Full Text] [Related]
39. Comparison of visual outcome and regression pattern of myopic choroidal neovascularization after intravitreal bevacizumab or after photodynamic therapy.
Hayashi K; Ohno-Matsui K; Teramukai S; Shimada N; Moriyama M; Hayashi W; Yoshida T; Tokoro T; Mochizuki M
Am J Ophthalmol; 2009 Sep; 148(3):396-408. PubMed ID: 19427991
[TBL] [Abstract][Full Text] [Related]
40. Intravitreal bevacizumab vs sub-tenon triamcinolone acetonide for choroidal neovascularization attributable to pathologic myopia.
Wakabayashi T; Ikuno Y; Gomi F; Hamasaki T; Tano Y
Am J Ophthalmol; 2009 Oct; 148(4):591-596.e1. PubMed ID: 19589497
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]